Published in
Elsevier, Clinical Lung Cancer, 6(21), p. 498-508.e2, 2020
DOI: 10.1016/j.cllc.2020.06.010
Links
Tools
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
Journal article published in 2020 by
Alessio Cortellini,
Alex Friedlaender,
Giuseppe L. Banna,
Giampiero Porzio,
Melissa Bersanelli 
,
Federico Cappuzzo,
Joachim G. J. V. Aerts,
Raffaele Giusti,
Emilio Bria,
Diego Cortinovis,
Francesco Grossi,
Maria R. Migliorino,
Domenico Galetta,
Francesco Passiglia,
Rossana Berardi
and other authors.
,
Federico Cappuzzo,
Joachim G. J. V. Aerts,
Raffaele Giusti,
Emilio Bria,
Diego Cortinovis,
Francesco Grossi,
Maria R. Migliorino,
Domenico Galetta,
Francesco Passiglia,
Rossana Berardi
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 